PharmAthene, Siga infectious news

The Delaware Court of Chancery court ordered Siga to pay PharmAthene $194.6 million in a case involving Siga’s smallpox antiviral Tecovirimat ( ST-246). The award consists of $113.1 million in lump sum expectation damages for PharmAthene’s lost profits for Tecovirimat and $81.5 million in pre-judgment interest and attorneys’ and expert witness fees. Additionally, Siga will be required to pay post judgment interest of $30,664 per day, beginning on Jan. 15. Siga filed an appeal, saying “the decision to award expectation damages is not supported by law with the amount of the award being completely speculative, conjectural and arbitrary.” ...